Motixafortide (Aphexda)

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 11:04, 31 October 2023 by Jwarner (talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

cyclic-peptide CXCR4 inhibitor

History of changes in FDA indication

2023-09-12: Approved for the mobilization of hematopoietic stem cells to peripheral blood prior to collection for autologous stem cell transplantation (ASCT) in patients with multiple myeloma. (Based on GENESIS)

Also known as

Brand name: Aphexda

Retrieved from "https://hemonc.org/w/index.php?title=Motixafortide_(Aphexda)&oldid=80094"